Ikena Oncology, Inc. (NASDAQ:IKNA) Short Interest Update

Ikena Oncology, Inc. (NASDAQ:IKNA) was the recipient of a significant increase in short interest during the month of February. As of February 15th, there was short interest totalling 154,100 shares, an increase of 34.1% from the January 31st total of 114,900 shares. Based on an average trading volume of 226,700 shares, the short-interest ratio is presently 0.7 days. Approximately 1.1% of the company’s shares are sold short.

Institutional Trading of Ikena Oncology

Several institutional investors and hedge funds have recently bought and sold shares of IKNA. FMR LLC increased its stake in shares of Ikena Oncology by 94.1% during the third quarter. FMR LLC now owns 38,374 shares of the company’s stock valued at $66,000 after purchasing an additional 18,607 shares in the last quarter. BNP Paribas Financial Markets purchased a new position in shares of Ikena Oncology during the 4th quarter worth $72,000. Squarepoint Ops LLC purchased a new position in shares of Ikena Oncology during the 4th quarter worth $72,000. Northern Trust Corp boosted its stake in shares of Ikena Oncology by 19.7% during the 4th quarter. Northern Trust Corp now owns 57,565 shares of the company’s stock worth $94,000 after acquiring an additional 9,456 shares during the last quarter. Finally, BBR Partners LLC boosted its stake in shares of Ikena Oncology by 550.0% during the 3rd quarter. BBR Partners LLC now owns 130,000 shares of the company’s stock worth $225,000 after acquiring an additional 110,000 shares during the last quarter. 75.00% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

Several equities analysts have recently commented on the stock. HC Wainwright reaffirmed a “buy” rating and set a $4.00 price objective on shares of Ikena Oncology in a research note on Monday, November 11th. Wedbush reaffirmed a “neutral” rating and set a $2.00 price objective on shares of Ikena Oncology in a research note on Monday, December 23rd.

Ikena Oncology Price Performance

Shares of IKNA opened at $1.35 on Thursday. Ikena Oncology has a one year low of $1.22 and a one year high of $1.94. The company has a 50-day simple moving average of $1.49 and a two-hundred day simple moving average of $1.62. The firm has a market capitalization of $65.15 million, a PE ratio of -1.10 and a beta of 0.48.

Ikena Oncology Company Profile

Ikena Oncology, Inc operates as an oncology company that develops differentiated therapies for patients in need that target nodes of cancer growth, spread, and therapeutic resistance in the United States. Its lead program is IK-930, an internally discovered, oral, TEAD1-selective, small molecule inhibitor of the Hippo pathway.